Display options
Share it on

Circulation. 2014 May 20;129(20):2005-12. doi: 10.1161/CIRCULATIONAHA.114.008643. Epub 2014 Mar 29.

Lack of concordance between empirical scores and physician assessments of stroke and bleeding risk in atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registry.

Circulation

Benjamin A Steinberg, Sunghee Kim, Laine Thomas, Gregg C Fonarow, Elaine Hylek, Jack Ansell, Alan S Go, Paul Chang, Peter Kowey, Bernard J Gersh, Kenneth W Mahaffey, Daniel E Singer, Jonathan P Piccini, Eric D Peterson,

Affiliations

  1. From the Duke University Medical Center, Durham, NC (B.A.S., J.P.P., E.D.P.); Duke Clinical Research Institute, Durham, NC (B.A.S., S.K., L.T., J.P.P., E.D.P.); UCLA School of Medicine, Los Angeles, CA (G.C.F.); Boston University School of Medicine, Boston, MA (E.H.); New York University School of Medicine, Lenox Hill Hospital, New York, NY (J.A.); Kaiser Permanente, Oakland, CA (A.S.G.); Janssen Pharmaceuticals, Inc., Raritan, NJ (P.C.); Lankenau Institute for Medical Research, Wynnewood, PA (P.K.); Mayo Clinic, Rochester, MN (B.J.G.); Stanford University School of Medicine, Palo Alto, CA (K.W.M.); and Harvard Medical School and Massachusetts General Hospital, Boston, MA (D.E.S.). [email protected]
  2. From the Duke University Medical Center, Durham, NC (B.A.S., J.P.P., E.D.P.); Duke Clinical Research Institute, Durham, NC (B.A.S., S.K., L.T., J.P.P., E.D.P.); UCLA School of Medicine, Los Angeles, CA (G.C.F.); Boston University School of Medicine, Boston, MA (E.H.); New York University School of Medicine, Lenox Hill Hospital, New York, NY (J.A.); Kaiser Permanente, Oakland, CA (A.S.G.); Janssen Pharmaceuticals, Inc., Raritan, NJ (P.C.); Lankenau Institute for Medical Research, Wynnewood, PA (P.K.); Mayo Clinic, Rochester, MN (B.J.G.); Stanford University School of Medicine, Palo Alto, CA (K.W.M.); and Harvard Medical School and Massachusetts General Hospital, Boston, MA (D.E.S.).

PMID: 24682387 PMCID: PMC4050636 DOI: 10.1161/CIRCULATIONAHA.114.008643

Abstract

BACKGROUND: Physicians treating patients with atrial fibrillation (AF) must weigh the benefits of anticoagulation in preventing stroke versus the risk of bleeding. Although empirical models have been developed to predict such risks, the degree to which these coincide with clinicians' estimates is unclear.

METHODS AND RESULTS: We examined 10 094 AF patients enrolled in the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF) registry between June 2010 and August 2011. Empirical stroke and bleeding risks were assessed by using the congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and previous stroke or transient ischemic attack (CHADS2) and Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) scores, respectively. Separately, physicians were asked to categorize their patients' stroke and bleeding risks: low risk (<3%); intermediate risk (3%-6%); and high risk (>6%). Overall, 72% (n=7251) in ORBIT-AF had high-risk CHADS2 scores (≥2). However, only 16% were assessed as high stroke risk by physicians. Although 17% (n=1749) had high ATRIA bleeding risk (score ≥5), only 7% (n=719) were considered so by physicians. The associations between empirical and physician-estimated stroke and bleeding risks were low (weighted Kappa 0.1 and 0.11, respectively). Physicians weighed hypertension, heart failure, and diabetes mellitus less significantly than empirical models in estimating stroke risk; physicians weighted anemia and dialysis less significantly than empirical models when estimating bleeding risks. Anticoagulation use was highest among patients with high stroke risk, assessed by either empirical model or physician estimates. In contrast, physician and empirical estimates of bleeding had limited impact on treatment choice.

CONCLUSIONS: There is little agreement between provider-assessed risk and empirical scores in AF. These differences may explain, in part, the current divergence of anticoagulation treatment decisions from guideline recommendations.

CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.gov. Unique identifier: NCT01165710.

© 2014 American Heart Association, Inc.

Keywords: atrial fibrillation; hemorrhage; risk assessment; stroke

References

  1. Value Health. 2006 Sep-Oct;9(5):348-56 - PubMed
  2. Eur Heart J. 2012 Jun;33(12):1500-10 - PubMed
  3. J Am Coll Cardiol. 1995 Nov 15;26(6):1432-6 - PubMed
  4. Heart. 2011 Dec;97(24):2046-50 - PubMed
  5. Thromb Haemost. 2011 Sep;106(3):528-38 - PubMed
  6. Am Heart J. 2011 Oct;162(4):606-612.e1 - PubMed
  7. Circulation. 1986 Dec;74(6 Pt 2):IV9-12 - PubMed
  8. J Am Coll Cardiol. 2011 Jul 19;58(4):395-401 - PubMed
  9. JAMA. 1999 May 19;281(19):1830-5 - PubMed
  10. J Gen Intern Med. 2005 Aug;20(8):686-91 - PubMed
  11. JAMA. 2001 Jun 13;285(22):2864-70 - PubMed
  12. Stroke. 1991 Aug;22(8):983-8 - PubMed
  13. J Am Coll Cardiol. 2012 Aug 28;60(9):861-7 - PubMed

Substances

MeSH terms

Publication Types

Grant support